​​Innovative therapies
                         Superior outcomes

August 2017:
    Paradox Pharmaceuticals receives MUMS user fee               waiver from FDA for clinical development of its lead         compound, daunomustine, as therapy for canine               lymphoma.


June 2017:
    Paradox Pharmaceuticals selected to present at the           Kansas City Animal Health Investment Forum in August.



May 2017:
    AD 198 study published in Journal of Cellular                   Biochemistry.


Latest News:

Redefining anthracyclines to create clinically effective, non-cardiotoxic agents for treating cancer in companion animals.

Products: